^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Immunostimulant

    Related drugs:
    16h
    Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer (clinicaltrials.gov)
    P2, N=29, Recruiting, National Cancer Institute (NCI) | Trial completion date: Nov 2027 --> Nov 2028
    Trial completion date
    |
    CD4 (CD4 Molecule)
    |
    Keytruda (pembrolizumab) • PRGN-2009
    16h
    Korean Post Marketing Surveillance for Comirnaty Injection (Bretovameran) (clinicaltrials.gov)
    P=N/A, N=660, Active, not recruiting, Pfizer | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    18h
    A Trial to Evaluate Tolerability and Immunogenicity of V540D in Healthy Adults (V540D-004) (clinicaltrials.gov)
    P1, N=72, Not yet recruiting, Merck Sharp & Dohme LLC
    New P1 trial
    |
    Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant)
    1d
    Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older (clinicaltrials.gov)
    P1/2, N=1470, Not yet recruiting, Sanofi Pasteur, a Sanofi Company
    New P1/2 trial
    1d
    HORIZON 1: A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19) (clinicaltrials.gov)
    P2, N=51, Completed, Janssen Vaccines & Prevention B.V. | N=98 --> 51
    Enrollment change
    1d
    A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age (clinicaltrials.gov)
    P1/2, N=1080, Completed, GlaxoSmithKline | Active, not recruiting --> Completed | Phase classification: P2 --> P1/2
    Trial completion • Phase classification
    |
    Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant)
    2d
    A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy People (clinicaltrials.gov)
    P1/2, N=1350, Not yet recruiting, BioNTech SE
    New P1/2 trial
    3d
    FPCV: The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan Infants (clinicaltrials.gov)
    P4, N=2100, Completed, London School of Hygiene and Tropical Medicine | Active, not recruiting --> Completed
    Trial completion
    3d
    ROSALIE: First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma (clinicaltrials.gov)
    P1/2, N=100, Completed, Enterome | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Mar 2024 | Trial primary completion date: Dec 2024 --> Jan 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • Avastin (bevacizumab) • EO2401
    3d
    Spencer: A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma (clinicaltrials.gov)
    P1/2, N=70, Terminated, Enterome | Active, not recruiting --> Terminated; Strategic decision
    Trial termination • Combination therapy • Checkpoint block • Metastases
    |
    Opdivo (nivolumab) • EO2401
    3d
    Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients (clinicaltrials.gov)
    P1/2, N=60, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
    |
    BRAF mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation
    |
    NOUS-209
    4d
    Clinical study on the protective mechanism of immune response of recombinant herpes zoster vaccine (CHO cell) based on multi-omics (ChiCTR2400090653)
    P1, N=80, Not yet recruiting, Wuxi Center for Disease Control and Prevention; Beijing Luzhu Biotechnology Co.,Ltd.
    New P1 trial
    |
    CD8 (cluster of differentiation 8) • IL2 (Interleukin 2) • CD40LG (CD40 ligand)
    4d
    Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of Longkoma Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris) Implanted in Populations of 6 Weeks and Older (ChiCTR2400089762)
    P1/2, N=580, Completed, Guangxi Zhuang Autonomous Region Centre for Disease Control and Prevention; Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
    New P1/2 trial
    6d
    PRGN-2009-201: PRGN-2009 in Combination with Pembrolizumab Versus Pembrolizumab in Patients with Recurrent or Metastatic Cervical Cancer (clinicaltrials.gov)
    P2, N=46, Recruiting, Precigen, Inc | Initiation date: Aug 2024 --> Nov 2024
    Trial initiation date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • PRGN-2009
    6d
    A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults (clinicaltrials.gov)
    P1/2, N=402, Not yet recruiting, SK Bioscience Co., Ltd.
    New P1/2 trial
    7d
    Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients (clinicaltrials.gov)
    P2, N=90, Recruiting, University of California, Davis | Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Mar 2025
    Trial completion date • Trial primary completion date
    7d
    A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases (clinicaltrials.gov)
    P3, N=39, Recruiting, Takeda | Not yet recruiting --> Recruiting
    Enrollment open
    8d
    A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination with an Investigational RNA-based Vaccine Against Malaria (clinicaltrials.gov)
    P1/2, N=177, Active, not recruiting, BioNTech SE | Recruiting --> Active, not recruiting
    Enrollment closed
    8d
    Study to Evaluate the Safety and Immune Response of an Investigational Vaccine for the Prevention of RSV (Respiratory Syncytial Virus) and (hMPV) Human Metapneumovirus Infection in Participants Aged 60 to 75 Years (clinicaltrials.gov)
    P1, N=390, Recruiting, Sanofi Pasteur, a Sanofi Company | Not yet recruiting --> Recruiting
    Enrollment open
    8d
    Study of the Plasmodium Vivax Transmission-blocking Vaccine Pvs230D1-EPA/Matrix-M to Assess Safety, Immunogenicity, and Transmission-blocking Activity in Healthy Malaria-naive Adults (clinicaltrials.gov)
    P1, N=59, Active, not recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting --> Active, not recruiting | N=200 --> 59 | Trial completion date: May 2025 --> Nov 2025 | Trial primary completion date: May 2025 --> Nov 2025
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    8d
    LYL845-101: A Study to Investigate LYL845 in Adults With Solid Tumors (clinicaltrials.gov)
    P1, N=108, Active, not recruiting, Lyell Immunopharma, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR • BRAF mutation
    |
    LYL845
    8d
    Tyme-88-Panct: A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P2/3, N=130, Terminated, Tyme, Inc | Completed --> Terminated; Sponsor's decision
    Trial termination • Metastases
    |
    gemcitabine • 5-fluorouracil • capecitabine • sirolimus • racemetyrosine (SM-88)
    8d
    A Study to Assess the Safety and Effectiveness of Two Experimental Malaria Vaccines (clinicaltrials.gov)
    P1/2, N=58, Active, not recruiting, University of Oxford | Recruiting --> Active, not recruiting | Trial completion date: Mar 2025 --> Mar 2026 | Trial primary completion date: Mar 2025 --> Jan 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    G6PD (Glucose-6-Phosphate Dehydrogenase)
    9d
    PHV02-C-102: Study to Evaluate Safety and Immunogenicity of a Prime-Boost Regimen of RVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects (clinicaltrials.gov)
    P1, N=120, Active, not recruiting, Public Health Vaccines LLC | Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2024 --> Nov 2024
    Enrollment closed • Trial primary completion date
    9d
    Evaluation of Safety and Immunogenicity of rVSVΔG-SEBOV-GP Vaccine in Adults With Good General Health (clinicaltrials.gov)
    P1, N=36, Completed, International AIDS Vaccine Initiative | Active, not recruiting --> Completed
    Trial completion
    9d
    GO39733: A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors (clinicaltrials.gov)
    P1, N=272, Active, not recruiting, Genentech, Inc. | Trial completion date: Nov 2024 --> Mar 2025 | Trial primary completion date: Nov 2024 --> Mar 2025
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • PGR negative
    |
    Tecentriq (atezolizumab) • autogene cevumeran (RG6180)
    10d
    Plateau Antibody Levels of a Recombinant (E.Coli) HPV Nonavalent Vaccine Versus Gardasil®9 in Young Women (clinicaltrials.gov)
    P=N/A, N=392, Active, not recruiting, Xiamen University | Not yet recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Mar 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant) • nonavalent HPV vaccine
    10d
    Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 16055 NFL Delta Gly4 Env Protein Trimer and Trimer 4571 Combined With 3M-052-AF + Alum Adjuvant and Ad4-Env145NFL Viral Particles as Heterologous Prime-boost Regimens in Adult Participants Without HIV. (clinicaltrials.gov)
    P1, N=45, Active, not recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD4 (CD4 Molecule)
    10d
    NGAM-13: Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS) (clinicaltrials.gov)
    P3, N=71, Completed, Octapharma | Active, not recruiting --> Completed
    Trial completion • Head-to-Head
    11d
    A Study to Evaluate VXA-CoV2-3.1 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection (clinicaltrials.gov)
    P2, N=10000, Recruiting, Vaxart
    New P2 trial
    11d
    Nanoradiosentizers with X ray-actuatable supramolecular aptamer building units for programmable immunostimulatory T cell engagement. (PubMed, Biomaterials)
    The CA-mediated post-IR tumor-T cell engagement could override the immunosuppressive barriers in TME and enhance T cell-mediated recognition and elimination of tumor cells while minimizing systemic toxicities. Overall, this work offers an innovative approach to enhance the radio-immunotherapeutic efficacy in the clinics.
    Journal
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    14d
    HPV Vaccination in HIV Infected and HIV Uninfected Adolescents in Eswatini (clinicaltrials.gov)
    P4, N=1403, Completed, Columbia University | Active, not recruiting --> Completed
    Trial completion
    |
    IFNG (Interferon, gamma) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • IL2 (Interleukin 2)
    |
    Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant)
    14d
    Live Attenuated Influenza Vaccine As a Nasal Model for Influenza Infection (clinicaltrials.gov)
    P4, N=25, Recruiting, University of Alabama at Birmingham | Suspended --> Recruiting
    Enrollment open
    |
    CFTR (CF Transmembrane Conductance Regulator)
    14d
    A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIV (clinicaltrials.gov)
    P=N/A, N=1, Completed, Pfizer | Active, not recruiting --> Completed
    Trial completion
    14d
    A Study to Learn About New COVID-19 RNA Vaccine Candidates for New Variants in Healthy Individuals (clinicaltrialsregister.eu)
    P2/3, N=723, BioNTech SE
    New P2/3 trial
    14d
    Immunogenicity and Safety of the Concomitant Administration of OVX836 and Quadrivalent Influenza Vaccine in Healthy Volunteers. (clinicaltrials.gov)
    P2, N=180, Completed, Osivax | Phase classification: P2a --> P2
    Phase classification
    14d
    Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma (clinicaltrials.gov)
    P1, N=11, Active, not recruiting, Dana-Farber Cancer Institute | N=20 --> 11
    Enrollment change • Combination therapy • Metastases
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Neo Vax (NEO-PV-01)
    14d
    MVA-BN-RSV Vaccine Trial (clinicaltrials.gov)
    P3, N=20419, Terminated, Bavarian Nordic | Completed --> Terminated; The trial was terminated after the first RSV season because of the failure to meet the primary outcome measures of vaccine efficacy
    Trial termination
    14d
    A Study of Pembrolizumab (MK-3475) With or Without V940 in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) (clinicaltrials.gov)
    P3, N=680, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • paclitaxel • pemetrexed • mRNA-4157
    16d
    Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation (clinicaltrials.gov)
    P2, N=7, Active, not recruiting, City of Hope Medical Center | N=12 --> 7
    Enrollment change • Triplex vaccine
    |
    Triplex (CMV-MVA vaccine)
    16d
    KSD-101 Therapy for EBV-associated Lymphomas: an Exploratory Clinical Trial (clinicaltrials.gov)
    P1, N=0, Withdrawn, Kousai Bio Co., Ltd. | Active, not recruiting --> Withdrawn
    Trial withdrawal
    |
    KSD-101
    16d
    Safety and Immunogenicity Study of SCB-1019T in Children (clinicaltrials.gov)
    P1, N=112, Not yet recruiting, Clover Biopharmaceuticals AUS Pty Ltd
    New P1 trial